Skip to main content

Table 3 Parameter estimates from the linear regression model for total cholesterol

From: Using imputed pre-treatment cholesterol in a propensity score model to reduce confounding by indication: results from the multi-ethnic study of atherosclerosis

Adjusted R2 = 0.44

Cholesterolpre-treated(N = 1286)

Covariates

β

(95% CI)

P-value

Cholesterolpost-treated (mg/dl)

0.53

(0.46,0.60)

<.001

Age (years)

-0.18

(-0.35,-0.01)

0.033

Gender – Male

-10.32

(-13.66,-6.98)

<.001

Race/ethnicity

   

White

--

--

--

Chinese

-6.21

(-11.71,-0.72)

0.027

Black

-7.62

(-11.63,-3.60)

<.001

Hispanic

-1.21

(-5.32,2.90)

0.565

Diabetes

   

Normal

--

--

--

IFG

0.23

(-3.80,4.26)

0.910

Untreated diabetes

2.69

(-9.46,14.85)

0.664

Treated diabetes

-9.00

(-12.91,-5.10)

<.001

Hypertension Meds – Yes

-5.43

(-8.79,-2.08)

0.002

HDLpost-treated

0.12

(-0.03,0.26)

0.107

triglycerides

0.03

(-0.00,0.05)

0.069

Atorvastatin

   

Yes – Low dose

28.31

(18.19,38.42)

<.001

Yes – High dose

42.84

(31.99,53.69)

<.001

Fluvastatin

   

Yes – Low dose

18.24

(1.01,35.47)

0.038

Yes – High dose

25.83

(13.15,38.51)

<.001

Lovastatin

   

Yes – Low dose

19.41

(8.61,30.21)

<.001

Yes – High dose

34.80

(20.87,48.74)

<.001

Pravastatin

   

Yes – Low dose

20.23

(8.69,31.77)

0.001

Yes – High dose

23.72

(8.71,38.73)

0.002

Simvastatin

   

Yes – Low dose

45.46

(22.98,67.94)

<.001

Yes – High dose

19.16

(-16.64,54.96)

0.294

Simvastatin*Cholesterolpost-treated Interaction

   

Yes – Low dose

-0.12

(-0.25,0.01)

0.071

Yes – High dose

0.11

(-0.11,0.32)

0.320

Rosuvastatin – Yes

38.36

(26.43,50.29)

<.001

Fibrate – Yes

7.00

(-3.76,17.77)

0.202

Resin – Yes

-7.76

(-31.48,15.96)

0.521

Niacin – Yes

-29.12

(-56.25,-2.00)

0.035

Niacin*Cholesterolpost-treated Interaction

0.12

(-0.02,0.27)

0.101

Ezetimibe – Yes

12.10

(2.27,21.94)

0.016